When do you plan to add bevacizumab to pembrolizumab/paclitaxel (KEYNOTE-B96) in patients with PD-L1 positive platinum-resistant ovarian cancer?

Colombo et al. PMID: 41974150

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

For an elderly woman with a platinum-resistant recurrence of a high-grade serous ovarian cancer who has been rendered NED surgically, is observation a reasonable approach?

Does the data for ENGOT-ov65/KEYNOTE-B96 (pembrolizumab + paclitaxel +/- bevacizumab) influence how you will incorporate IO therapy into platinum-resistant ovarian cancer?

What are your top takeaways from SGO 2026?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
TrialMatch
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.